HER2 as a novel therapeutic target for cervical cancer
Metrics: PDF 1426 views | HTML 1470 views | ?
Doo-Yi Oh1,2,3,*, Seokhwi Kim1,*, Yoon-La Choi1,2,3,*, Young Jae Cho4,*, Ensel Oh2,3, Jung-Joo Choi4, Kyungsoo Jung3, Ji-Young Song2, Suzie E. Ahn2, Byoung-Gie Kim4, Duk-Soo Bae4, Woong-Yang Park3,5, Jeong-Won Lee2,3,4,*, Sangyong Song1,2,*
1Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Institute for Refractory Cancer Research, Samsung Medical Center, Seoul, Korea
3Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea
4Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
5Samsung Genome Institute, Samsung Medical Center, Seoul, Korea
*These authors have contributed equally to this work
Jeong-Won Lee, e-mail: email@example.com
Sangyong Song, e-mail: firstname.lastname@example.org
Keywords: HER2, cervical cancer, targeted therapy, patient-derived xenograft, trastuzumab
Received: June 09, 2015 Accepted: September 11, 2015 Published: September 21, 2015
Surgery and radiation are the current standard treatments for cervical cancer. However, there is no effective therapy for metastatic or recurrent cases, necessitating the identification of therapeutic targets. In order to create preclinical models for screening potential therapeutic targets, we established 14 patient-derived xenograft (PDX) models of cervical cancers using subrenal implantation methods. Serially passaged PDX tumors retained the histopathologic and genomic features of the original tumors. Among the 9 molecularly profiled cervical cancer patient samples, a HER2-amplified tumor was detected by array comparative genomic hybridization and targeted next-generation sequencing. We confirmed HER2 overexpression in the tumor and serially passaged PDX. Co-administration of trastuzumab and lapatinib in the HER2-overexpressed PDX significantly inhibited tumor growth compared to the control. Thus, we established histopathologically and genomically homologous PDX models of cervical cancer using subrenal implantation. Furthermore, we propose HER2 inhibitor-based therapy for HER2-amplified cervical cancer refractory to conventional therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.